PuraPharm Corporation Income Statement

Financials in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	336.11	382.09	406.86	448.07	659.59
Revenue Growth (YoY)	-12.03%	-6.09%	-9.20%	-32.07%	9.60%
Cost of Revenue	155.96	176.95	190.23	185.37	236.24
Gross Profit	180.16	205.14	216.63	262.7	423.35
Selling, General & Admin	204.54	224.39	263.18	315.3	388.46
Other Operating Expenses	-	0.62	3.93	5.11	2.73
Operating Expenses	196.38	224.01	269.83	330.95	408.22
Operating Income	-16.22	-18.86	-53.2	-68.25	15.14
Interest Expense	-20.72	-23.71	-27.41	-24.18	-27.03
Interest & Investment Income	-	0.35	0.29	0.48	0.36
Earnings From Equity Investments	-0.09	-0.31	-0.15	-	-
Currency Exchange Gain (Loss)	-	-0.87	-0.41	-0.08	0.71
Other Non Operating Income (Expenses)	0.64	4.49	9.24	12.25	1.22
EBT Excluding Unusual Items	-36.4	-38.93	-71.63	-79.79	-9.6
Impairment of Goodwill	-	-	-3.05	-	-67.35
Gain (Loss) on Sale of Investments	-0.57	1.44	-0	0.17	0.3
Gain (Loss) on Sale of Assets	3.85	11.12	2.02	1.73	-0.01
Asset Writedown	-1.29	-2.77	-29.66	-41.3	-48.66
Other Unusual Items	-	-	-	-	8.12
Pretax Income	-34.41	-29.14	-102.31	-119.18	-117.19
Income Tax Expense	0.81	6.3	3.77	1.03	4.69
Net Income	-35.22	-35.44	-106.08	-120.21	-121.88
Net Income to Common	-35.22	-35.44	-106.08	-120.21	-121.88
Shares Outstanding (Basic)	419	395	395	395	394
Shares Outstanding (Diluted)	419	395	395	395	394
Shares Change (YoY)	6.00%	-	0.12%	0.22%	6.01%
EPS (Basic)	-0.08	-0.09	-0.27	-0.30	-0.31
EPS (Diluted)	-0.08	-0.09	-0.27	-0.30	-0.31
Free Cash Flow	-	89.18	60.43	67.68	-17.61
Free Cash Flow Per Share	-	0.23	0.15	0.17	-0.04
Gross Margin	53.60%	53.69%	53.24%	58.63%	64.18%
Operating Margin	-4.83%	-4.94%	-13.08%	-15.23%	2.30%
Profit Margin	-10.48%	-9.28%	-26.07%	-26.83%	-18.48%
Free Cash Flow Margin	-	23.34%	14.85%	15.10%	-2.67%
EBITDA	17.27	14.63	-29.15	-42.11	40.12
EBITDA Margin	5.14%	3.83%	-7.17%	-9.40%	6.08%
D&A For EBITDA	33.49	33.49	24.05	26.14	24.98
EBIT	-16.22	-18.86	-53.2	-68.25	15.14
EBIT Margin	-4.83%	-4.94%	-13.08%	-15.23%	2.30%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.